Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The ...

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A ...

On Wednesday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.85 or 2.98% from the prior close of $28.5. The stock opened at $28.7 and ...

A court ruled in favor of Exelixis in the oncology company's patent-infringement lawsuit against MSN Laboratories.